These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27321774)

  • 21. Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects.
    Mu S; Tang Z; Novotny W; Tawashi M; Li TK; Ou Y; Sahasranaman S
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):391-399. PubMed ID: 31875923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rifampin Reduces the Plasma Concentrations of Oral and Intravenous Hydromorphone in Healthy Volunteers.
    Lohela TJ; Poikola S; Neuvonen M; Niemi M; Backman JT; Olkkola KT; Lilius TO
    Anesth Analg; 2021 Aug; 133(2):423-434. PubMed ID: 33177323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy Subjects.
    Jiang X; Dutreix C; Jarugula V; Rebello S; Won CS; Sun H
    Clin Pharmacol Drug Dev; 2017 Jan; 6(1):19-26. PubMed ID: 27138546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer.
    Yang J; Pradhan RS; Rosen LS; Graham AM; Holen KD; Xiong H
    J Clin Pharm Ther; 2014 Dec; 39(6):680-4. PubMed ID: 25047139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leveraging Human Plasma-Derived Small Extracellular Vesicles as Liquid Biopsy to Study the Induction of Cytochrome P450 3A4 by Modafinil.
    Rodrigues AD; Wood LS; Vourvahis M; Rowland A
    Clin Pharmacol Ther; 2022 Feb; 111(2):425-434. PubMed ID: 34623637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absence of clinically relevant drug-drug interaction between odanacatib and digoxin after concomitant administration.
    Stoch SA; Witter R; Hreniuk D; Liu C; Zajic S; Mehta A; Brandquist C; Dempsey C; Degroot B; Stypinski D; Denker A; Wagner JA
    Int J Clin Pharmacol Ther; 2013 Aug; 51(8):688-92. PubMed ID: 23782582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants.
    Ogasawara K; Kam J; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):369-377. PubMed ID: 34019108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects.
    Li T; Li X; Jiang X; Wang C; Sun F; Liu Y; Lin P; Shi P; Fu Y; Gao X; Zhang Y; Cao Y
    Cancer Chemother Pharmacol; 2022 Nov; 90(5):409-415. PubMed ID: 36107220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.
    Nomoto M; Zamora CA; Schuck E; Boyd P; Chang MK; Aluri J; Siu YA; Lai WG; Yasuda S; Ferry J; Rege B
    Br J Clin Pharmacol; 2018 May; 84(5):952-960. PubMed ID: 29341245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
    Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
    J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK-788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers.
    Zhang S; Jin S; Griffin C; Feng Z; Lin J; Venkatakrishnan K; Gupta N
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1044-1053. PubMed ID: 34145979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans.
    Kassahun K; McIntosh I; Koeplinger K; Sun L; Talaty JE; Miller DL; Dixon R; Zajic S; Stoch SA
    Drug Metab Dispos; 2014 May; 42(5):818-27. PubMed ID: 24553380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants.
    Chen J; Xu H; Pawlak S; James LP; Peltz G; Lee K; Ginman K; Bergeron M; Pithavala YK
    Adv Ther; 2020 Feb; 37(2):745-758. PubMed ID: 31863284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa.
    Vakkalagadda B; Frost C; Byon W; Boyd RA; Wang J; Zhang D; Yu Z; Dias C; Shenker A; LaCreta F
    Am J Cardiovasc Drugs; 2016 Apr; 16(2):119-27. PubMed ID: 26749408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects.
    Hamilton M; Wolf JL; Drolet DW; Fettner SH; Rakhit AK; Witt K; Lum BL
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):613-21. PubMed ID: 24474302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects.
    Luedtke D; Marzin K; Jungnik A; von Wangenheim U; Dallinger C
    Eur J Drug Metab Pharmacokinet; 2018 Oct; 43(5):533-541. PubMed ID: 29500603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole.
    Liu X; Zhang Y; Chen Q; Zhan Y; Wang Q; Hu C; Yu C; Guo Z; Chen X; Zhong D
    J Clin Pharmacol; 2018 Mar; 58(3):347-356. PubMed ID: 28967981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects.
    Mukai M; Uchimura T; Zhang X; Greene D; Vergeire M; Cantillon M
    J Clin Pharmacol; 2018 Feb; 58(2):193-201. PubMed ID: 28881378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Rifampicin on the Pharmacokinetics of a Single Dose of Vemurafenib in Patients With BRAF
    Zhang W; McIntyre C; Forbes H; Gaafar R; Kohail H; Beck JT; Plestina S; Bertran E; Riehl T
    Clin Pharmacol Drug Dev; 2019 Aug; 8(6):837-843. PubMed ID: 30570831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects.
    Xu H; O'Gorman M; Tan W; Brega N; Bello A
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1441-9. PubMed ID: 26381275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.